When individuals in high-income countries are empowered to self-adjust insulin doses, with access to tools such as continuous glucose monitors and insulin pumps, low- and middle-income countries often rely on fixed insulin regimens managed under strict medical supervision, largely due to limited diabetes education, health infrastructures, and access to diagnostic tools [26,27,28]. The gene discussed is INS; the disease is diabetes mellitus.